Use of GLP-1 receptor agonists continues to shift rapidly, with early April developments highlighting changes in pricing models, drug access, regulatory oversight and personalized care.
Here are five notable GLP-1 developments:
1. Pricing models diversify to boost access
Novo Nordisk launched a multimonth subscription program for Wegovy, with prices ranging from $329 per month for three months to $249 per month for a 12-month plan, offering up to $1,200 in annual savings for self-pay patients. The model is designed to reduce cost variability and improve adherence, a persistent challenge for GLP-1 therapies. The company also introduced a higher-dose Wegovy HD, a 7.2-milligram injection priced at $399 per month, expanding dosing options beyond the previous 2.4-milligram maximum.
2. Oral GLP-1 competition grows, distribution expands
On April 1, the FDA approved Eli Lilly’s daily GLP-1 pill, Foundayo, for adults with obesity or overweight with at least one weight-related condition. The drug launched April 6 with starting prices at $149 per month for self-pay patients and is available through Amazon Pharmacy, which offers same-day delivery in nearly 3,000 locations, with plans to expand to 4,500 by year-end.
3. FDA tightens oversight of compounded products
The FDA said pharmacies must stop compounding GLP-1 drugs once branded versions are no longer listed in shortage, emphasizing the exemption is temporary and tied to supply conditions. The agency warned continued production of “essentially copies” could trigger enforcement action. In March, the FDA also issued 30 warning letters to companies over misleading claims about compounded GLP-1 products as part of a broader crackdown on the rapidly expanding market.
4. Next-generation drugs aim for longer dosing, new use cases
Drugmakers are developing next-generation GLP-1 therapies designed to improve convenience and expand use, according to an April 7 report in The Wall Street Journal. Pipeline candidates include once-monthly injectable GLP-1s from Pfizer and Amgen expected around 2028, as well as additional weekly therapies from Eli Lilly and Roche, and a daily oral therapy from Structure Therapeutics projected for 2029. Novo Nordisk is also developing a next-generation weekly injection that could reach the market by late 2026. Some drugs in development may target more severe obesity with greater weight loss, while others could be used as maintenance therapies after initial treatment, signaling a shift toward more tailored, long-term care models.
5. Genetics may shape future prescribing
A study published April 8 in Nature analyzing data from 27,885 patients found genetic variants linked to improved weight loss outcomes among GLP-1 users, with patients losing about 0.76 kilograms more per variant copy. Researchers also identified genetic associations tied to side effects such as nausea and vomiting, suggesting genetic testing could help predict both treatment response and tolerability.
The post 5 updates on GLP-1 drugs: Pricing, access, FDA scrutiny appeared first on Becker's Hospital Review | Healthcare News & Analysis.
Source: Read Original Article
